診療科のご案内

ホーム > 診療科・部門のご案内 > 呼吸器内科・腫瘍内科 > 研究業績

研究業績

 

2018年の業績

英文図書
1)Nakano T, Shibata E, Kuribayashi K, Yoshikawa Y, Ohmuraya M. Pulmonary Malignancies:Mesothelioma--What are the roles of genetic factors in the pathogenesis of mesothelioma? In"Clinical Relevance of Genetic Factors in Pulmonary Diseases"(Ed. Kaneko T), pp.207-224, Springer Nature Singapore Pte Ltd. 2018.

英文原著
1)Hashimoto M, Tanaka F, Yoneda K, Takuwa T, Matsumoto S, Okumura Y, Kondo N, Tsujimura T, Nakano T, Hasegawa S. Positive correlation between postoperative tumor recurrence and changes in circulating tumor cell counts in pulmonary venous blood (pvCTC) during surgical manipulation in non-small cell lung cancer, J Thorac Dis 2018;10(1):298-306
2)Hashimoto M, Tanaka F, Yoneda K, Takuwa T, Kuroda A, Matsumoto S, Okumura Y, Kondo N, Tsujimura T, Nakano T, Hasegawa S. The clinical value of circulating tumour cells (CTCs) in patients undergoing pulmonary metastasectomy for metastatic colorectal cancer. J Thorac Dis 10(3):1569-1577, 2018

和文総説
1)中野孝司、 石垣裕敏、中島康博、飯田慎一郎. 悪性胸膜中皮腫. 呼吸器内科33:229-237, 2018
2)中野孝司、石垣裕敏、中島康博、前田 純、三井秀紀、大口善郎、飯田慎一郎. アスベストの生体影響―アスベスト関連疾患の病態と研究動向. 環境技術(環境技術学会) 47(3)146-153, 2018
3)中野孝司、石垣裕敏、中島康博、河原正明、前田 純、飯田慎一郎. 中皮腫. 主要呼吸器疾患の診断と治療. 呼吸器内科 34(Suppl 1)1-7, 2018
 

2017年の業績

英文原著
1) Cho H, Matsumoto S, Fujita Y, Kuroda A, Menju T, Sonobe M, Kondo N, Torii I, Nakano T, Lara PN, Gandara DR, Date H, Hasegawa S. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma. J Thorac Oncol.12:477-490, 2017
2) Kanemura S, Kuribayashi K, Funaguchi N, Shibata E, Mikami K, Doi H, Kitajima K, Hasegawa S, Nakano T. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma. Eur J Radiol. 86:92-98, 2017
3) Kitajima K, Doi H, Kuribayashi K, Hashimoto M, Tsuchitani T, Tanooka M, Fukushima K, Nakano T, Hasegawa S, Hirota S. Prognostic value of pretreatment volume-based quantitative 18F-FDG PET/CT parameters in patients with malignant pleural mesothelioma. Eur J Radiol. 86:176-183, 2017
4) Takuwa T, Hashimoto M, Matsumoto S, Kondo N, Kuribayash K, Nakano T, Hasegawa S. Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy. Int J Clin Oncol. 2017 Apr 24. doi: 10.1007/s10147-017-1126-x. [Epub ahead of print]
5) Fujimoto E, Kijima T, Kuribayashi K, Negi Y, Kanemura S, Mikami K, Doi H, Kitajima K, Nakano T. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. Expert Review of Anticancer Therapy, 2017, DOI: 10.1080/14737140.2017.1340157
6) Scagliotti GV, Gaafar R, Nowak AK, Reck M, Tsao AS, van Meerbeeck J, Vogelzang NJ, Nakano T, von Wangenheim U, Velema D, Morsli N, Popat S. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. Clin Lung Cancer. 2017 Mar 22. pii: S1525-7304(17)30087-6. doi: 10.1016/j.cllc.2017.03.010. [Epub ahead of print]
7) Kataoka Y, Yamamoto Y, Otsuki T, Kaku S, Maehashi-Wada N, Fukuma S, Hirabayashi M, Nakano T, Fukuhara S. External validation of prognostic indices for overall survival of malignant pleural mesothelioma. Lung Cancer. 113:88-92, 2017

和文著書
1) 中野孝司:胸膜腫瘍、今日の治療指針2017 年度版(福井次矢、高木 誠、小室一成 編)、p.306, 医学書院、2017
2) 中野孝司. 胸膜中皮腫. 呼吸器疾患:Clinical Radiological-Pathologicalアプローチ. 編集:藤田次郎、大朏祐治. p.244-248, 南江堂, 2017
3) 中野孝司. 胸膜疾患. 内科学 第11版. 総編集:矢崎義雄. p.848-853, 朝倉書店, 2017
4) 中野孝司. 胸膜腫瘍(悪性胸膜中皮腫を含む). 1336専門家による私の治療 2017-18年度版. 監修:猿田享男、北村惣一朗. p.234-236, 日本医事新報社, 2017

和文総説
1) 中野孝司、飯田慎一郎. 悪性中皮腫の臨床所見と内科治療のupdate, 医学のあゆみ. 261;163-167, 2017
2) 中野孝司、中島康博、石垣裕敏、河原正明、前田 純、飯田慎一郎. アスベスト吸入と疾患. 成人病と生活習慣病 特集「仕事と病気」47;945-949, 2017
3) 中野孝司. 胸膜中皮腫に対する薬物療法、癌と化学療法44(13):2041-2047, 2017
 

2016年の業績

図 書
1) Takashi Nakano, Kozo Kuribayashi, Soon-Hee Jung, Hyoung-Ryoul Kim. Epidemiology of Malignant Pleural Mesothelioma in Japan anf Korea. In"Malignant Pleural Mesothelioma. Present Status and Future(Ed. Tommaso Mineo), 73-82, Bentham e-Book. 2016

原 著
1) Tabata C, Tabata R, Nakano T.  Calpeptin Prevents Malignant Pleural Mesothelioma Cell Proliferation via the Angiopoietin1/Tie2 System.  Asian Pac J Cancer Prev. 17(7):3405-9, 2016
2) Eguchi R, Nakano T, Wakabayashi I. Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells. Oncogene. 2016 Jun 27. doi: 10.1038/onc.2016.226. [Epub ahead of print]
3) Rusch VW, Chansky K, Kindler HL, Nowak AK, Pass HI, Rice DC, Shemanski L, Galateau-Sallé F, McCaughan BC, Nakano T, Ruffini E, van Meerbeeck JP, Yoshimura M; Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC Mesothelioma Staging Project: Proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma. J Thorac Oncol. 2016 Sep 27. pii: S1556-0864(16)31074-7. doi: 10.1016/j.jtho.2016.09.124.
4) Kuribayashi K, Funaguchi N, Nakano T. Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma. J Cancer Res Ther. 12(2):528-34, 2016. doi: 10.4103/0973-1482.174185.
5) Hasegawa S, Okada M, Tanaka F, Yamanaka T, Soejima T, Kamikonya N, Tsujimura T, Fukuoka K, Yokoi K, Nakano T. Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial). Int J Clin Oncol. 2016 Jun;21(3):523-30.
6) Yoshikawa Y, Emi M, Hashimoto-Tamaoki T, Ohmuraya M, Sato A, Tsujimura T, Hasegawa S, Nakano T, Nasu M, Pastorino S, Szymiczek A, Bononi A, Tanji M, Pagano I, Gaudino G, Napolitano A, Goparaju C, Pass HI, Yang H, Carbone M. High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13432-1343xz7.

総 説
1) Nakano T, Kuribayashi K, Koji Mikami K. Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil, Expert Rev Anticancer Ther. 2016 Oct 8:1-3. [Epub ahead of print]

症例報告
1) Kanemura S, Kuribayashi K, Moriya Y, Shimizu S, Tsujimura T, Nakano T. Pemetrexed for epithelioid haemangioendothelioma of the pleura. Respirol Case Rep. 2016 Sep 25;4(6):e00191.
2) 飯田 慎一郎, 松本 吉矢, 大搗 泰一郎, 河原 正明 喀血にて発見された気管支動脈蔓状血管腫の1例 気管支学 38;179-182, 2016

「研究業績」に関連するページ